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The number of identified monogenic causes of childhood-onset autoimmunity due to 
nodal and extranodal lymphoproliferation has increased. These pathogenic genetic 
variants provide the potential for pathway-specific treatment. Novel variants also require 
pathway-specific verification. In this report, we describe a 14-year-old patient with a 
novel variant in STAT3. We report clinical and laboratory findings that support STAT3 
p.G419R as a novel pathogenic STAT3 gain-of-function variant.
Keywords: stat3 transcription factor, gain-of-function mutations, autoimmune lymphoproliferative syndrome, 
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INtRoDUCtIoN
In recent years, multiple monogenic causes of early-onset autoimmunity/lymphoproliferation have 
been identified. These include CTLA4, LRBA, PIK3CD, PIK3R1, and STAT3 gain-of-function (GOF) 
(1–9). CTLA4 and LRBA patients can present with autoimmune cytopenias, lymphoproliferation, 
hypogammaglobulinemia, and lymphocytic infiltration of non-lymphoid organs. Patients with 
PIK3CD and PIK3R1 variants leading to increased signaling can present with lymphoproliferation, 
recurrent sinopulmonary infections, progressive airway damage, and chronic herpesvirus viremia. 
Patients with STAT3 GOF can present with cytopenias, lymphoproliferation, multi-organ autoim-
munity, short stature, and hypogammaglobulinemia. These can be added to previously known 
immune dysregulatory disorders, such as immunodysregulation polyendocrinopathy enteropathy 
X-linked syndrome (IPEX), autoimmune polyendocrinopathy, candidiasis ectodermal dystrophy/
dysplasia, and autoimmune lymphoproliferative syndrome (ALPS) due to variants in FOXP3, AIRE 
or FAS, FAS ligand, and caspase-10 (10–12), respectively. The identification of new syndromes makes 
it more fruitful to search for pathogenic variants in symptomatic patients and can potentially provide 
pathway-specific management options.
Case RepoRt
The patient is a 14-year-old Caucasian male born full term with no complications. He developed 
lymphadenopathy at age 3 leading to an excisional biopsy of an axillary node, which showed normal 
lymph node tissue. His mother denied noticeable persistent lymphadenopathy. At age 9, he developed 
autoimmune anemia and thrombocytopenia responsive to IVIg and steroids. Lymphadenopathy was 
not documented at this time. This led to a work up for autoimmune lymphoproliferative syndrome 
(ALPS). He was found to have normal numbers of double negative alpha/beta T cells with no B220+ 
DNT cells. He had two subsequent episodes of autoimmune hemolytic anemia. The most recent 
FIGURe 1 | Chest Ct of patient prior to treatment with mycophenolic 
acid showing multiple infiltrates.
FIGURe 2 | patient has decreased t regulatory cell (t reg) numbers 
and expresses less CD25. (a) Flow cytometric analysis of T reg 
populations, gated on CD4+ T cells. (B) T regs have decreased CD25 
expression, gated on CD4+ FOXP3+ CD127low cells. Dashed line shows 
naïve (CD45RO negative) T cells from a healthy control to show negative 
CD25 staining. Experiments were repeated at least twice with at least two 
healthy controls for each experiment.
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occurred at age 11 and he was treated with a 4-week course of 
rituximab. Between episodes, he was asymptomatic and was tak-
ing no medications. The patient had no history of significant or 
severe infections.
At age 13, the patient developed back pain, fever, shortness of 
breath, and cough. He did not improve despite multiple rounds 
of antibiotics for presumed pneumonia. He was admitted for IV 
antibiotic treatment. A chest CT showed mediastinal adenopathy 
and irregular nodular pulmonary infiltrates. A sputum culture was 
positive for Candida and the patient was treated with antifungals. 
In total, he received 29  days of amphotericin and micofungin. 
A bronchoscopy culture was negative for bacteria and fungus. A 
lung biopsy showed an atypical interstitiital lymphoplasmacytic 
infiltrate, suggesting an underlying lymphoproliferative process. 
Bacterial and fungal cultures of the lung were also negative. 
During his admission he was noted to have IgG <  155  mg/dL 
(low), IgM 354  mg/dL (high), and IgA 8.7  mg/dL (low). His 
hypogammaglobinemia was treated with IVIg. He gradually 
improved and was discharged.
He was then referred to our institution for further work up and 
treatment. Written and informed consent was obtained from the 
patient and his family members. This study was approved by the 
Institutional Review Board of the National Institutes of Health. At 
presentation he reported being in his normal state of health. He 
was greater than 50th percentile for height and weight. He has no 
history of arthritis. He reported shortness of breath while playing 
baseball. His oxygen saturation was 100% at rest but decreased to 
92% during a 6-minute walk test. His CT scan showed multiple 
nodules throughout the lung (Figure  1). Of note, many larger 
lesions seen in prior CT scans had decreased in size or resolved 
and lesions in new locations were appreciated. Lymphadenopathy 
and splenomegaly were also noted.
Laboratory studies showed WBC of 10.36 K/dL, hemoglobin 
12.6 g/dL, and platelet count of 386 K/μL. CMV and EBV were not 
detected by PCR of the blood. The patient did have abnormalities 
with decreased IgA (5 mg/dL) and IgG (135 mg/dL), elevated IgM 
(484 mg/dL), and IgE level was <1.0 IU/mL. Analysis of B cells 
showed normal total (13.4%, 256/μL) and switched memory 
(CD20+, CD27+, IgM−, 0.3%, 6/μL) B cells, and undetectable 
unswitched memory B cells (CD20+, CD27+, IgM+). B12 level 
was 921. At the time of this analysis, he had last received IVIg 
3 months prior and rituximab treatment was more than 2 years 
prior. Laboratory analysis further revealed decreased regula-
tory T cells with decreased CD25 expression (Figure 2). There 
were variable responses of phosphorylation of STAT (pSTAT) 
proteins to cytokine stimuli, which did not lead to a clear pattern 
(Figure 3) (8).
Targeted genetic testing using a panel of more than 150 
known and predicted immunity-related genes, including CTLA4, 
LRBA, STAT3, PIK3CD, PIK3R1, FOXP3, AIRE, FAS, FASLG, 
and CASP10, yielded only one rare variant of interest. A novel, 
heterozygous missense mutation in STAT3 c.1255G>C, p.G419R 
was found in the DNA binding domain just a few amino acids 
away from several other reported STAT3 GOF mutations and 
confirmed by Sanger sequencing. This variant was predicted to 
be deleterious by modeling with CADD phred score of 25.3 (13). 
Inheritance is unknown. GOF activity was confirmed using a 
luciferase assay, as previously reported (Figure 4) (8).
DIsCUssIoN
Autoimmune lymphoproliferative syndrome-FAS is the best 
known of the autoimmune/lymphoproliferative disorders. In a 
FIGURe 4 | p.G419R stat3 variant shows increased stat3 activity at 
baseline. Wild-type (WT) or mutant STAT3 plasmids were co-transfected 
into STAT3-deficient cells along with a STAT3-responsive luciferase reporter, 
followed by measurement of luciferase at 48 h (8). Averages shown are from 
four independent experiments.
FIGURe 3 | phosphorylation of stat1 and stat5 in response to 
stimulus. Peripheral blood mononuclear cells from the patient and a healthy 
control were stimulated with IL-6 (25 ng/mL) (a) and IL-2 (200 ng/mL) (B) for 
20 min. The cells were fixed using 4% paraformaldehyde and permeabilized 
with methanol, then stained with antibody and analyzed by flow cytometry. 
Cells were gated on CD4+ (a) or CD4+, pSTAT5+ (B) cells. Dashed line 
shows unstimulated cells from a healthy control. Experiments were repeated 
at least twice with at least two healthy controls for each experiment.
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case such as this patient when the number DNT cells, elevated 
in ALPS, are normal or there is lymphoproliferative infiltration 
of non-lymphoid organs, such as the lung, further testing for 
an alternative genetic diagnosis should be considered. Both 
loss-of-function (LOF) and GOF pathogenic variants have been 
described in STAT3-related disease. STAT3 LOF, which leads 
to autosomal dominant hyper-IgE syndrome does not fit this 
patient’s phenotype (14). However, his presentation is similar 
to patients with STAT3 GOF which can mimic ALPS, IPEX or 
IPEX-like disorders, and STAT5b-deficiency (8, 9, 15).
It is not clear that the Candida found during this patient’s 
hospitalization was pathogenic and he does not otherwise have 
a history of infections. A subset of STAT3 GOF patients can 
have infections expected by hypogammaglobulinemia and 
mycobacterial infection has been reported in one patient. We 
do not have IgG levels prior to rituximab treatment. While 
prolonged hypogammaglobulinemia post-rituximab is possible, 
the majority of patients treated for autoimmunity do not require 
Ig replacement 2 years after rituximab treatment (16, 17). Thus, 
his hypogammaglobulinemia is likely due to intrinsic immune 
dysregulation as reported with STAT3 GOF.
Given the entire clinical picture, his pulmonary pathology is 
most consistent with lymphoproliferation, a finding in multiple 
STAT3 GOF patients. Despite reporting only mild exercise intol-
erance on presentation to our institution, the patient was found 
to have significant pulmonary infiltration on CT scan. His lung 
biopsy was consistent with a lymphoproliferative process. In a 
retrospective study of patients with ALPS-like phenotype and 
findings on pulmonary CT scan, 89% were asymptomatic (18). 
Because of the patient’s exercise intolerance and extensive pulmo-
nary lesions he was started on immunosuppression. In addition 
to IVIg to treat his hypogammaglobulinemia, mycophenolic acid 
was initiated for his lymphoproliferative lung disease, which he 
has tolerated well. The patient does not have bronchiectasis, and 
his pulmonary changes may be reversible. Repeat chest imaging is 
planned. Mycophenolic acid has been used successfully in similar 
lymphoproliferative patients, including some that were later found 
to have STAT3 GOF (19). The importance of the diagnosis and 
confirmation of this STAT3 GOF variant as pathogenic arises if 
this patient requires additional treatment as potential treatments 
for STAT3 GOF patients include upstream inhibitors, such as 
tocilizumab (anti-IL-6 receptor monoclonal antibody) and Janus 
kinase inhibitors. Specific STAT3 inhibitors are currently being 
evaluated in clinical trials for cancer.
As genetic sequencing becomes more prevalent, the impor-
tance of verification of genetic variants will become more impor-
tant. In this case, the clinical presentation and the T regulatory 
cell profile were consistent with that of other known STAT3 GOF 
patients. However, interpretation of laboratory studies may be 
complicated in STAT3 GOF patients by systemic immune sup-
pressants often administered prior to diagnosis. In this case, the 
patient did not have multi-organ autoimmunity or short stature 
and the pSTAT responses to multiple cytokines did not yield a 
clear picture of pSTAT1 and pSTAT5 suppression as seen in pri-
mary cells from a number of STAT3 GOF patients (8). Therefore, 
we functionally confirmed that the STAT3 p.G419R variant leads 
to a 3.7-fold increase of STAT3 transcriptional activity at baseline 
compared to wild-type STAT3 (Figure 4).
We report clinical and laboratory findings that support STAT3 
p.G419R as a novel pathogenic STAT3 GOF variant. This case 
illustrates the importance of a genetic diagnosis in syndromes 
of lymphoproliferation and immunedysregulation. Proper diag-
nosis can lead to decreased use of unnecessary antimicrobials, 
more expedient use of immune suppression and appropriate 
monitoring.
etHICs stateMeNt
This study was carried out in accordance with the recommenda-
tions of NIH IRB with written informed consent from all subjects. 
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All subjects gave written informed consent in accordance with 
the Declaration of Helsinki. The protocol 14-I-0206 was approved 
by the NIH IRB.
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